Axsome's AXS-05 shows strong efficacy in treating Alzheimer's Disease Agitation, with significant CMAI score reductions.

In a report released yesterday, Graig Suvannavejh from Mizuho Securities maintained a Buy rating on Adaptimmune Therapeutics (ADAP – Research ...

In Q4 2024, the Lazard US Equity Concentrated Portfolio underperformed its benchmark. Click here to read the full commentary.

Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Meeting to be held in New York on March 18 at 6 pm hosted by Truist. Light Up your Portfolio with Spark:Easily identify stocks' risks and ...

Charles Schwab Investment Management Inc. raised its holdings in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free ...

Arizona State Retirement System lifted its holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report) by 1.8% in the ...

Axsome's depression drug, Auvelity, is driving the top line while Sunosi diversifies its business. The recent FDA nod for Symbravo also bodes well.

We recently published a list of 10 Best Performing Growth Stocks in 2025 In this article, we are going to take a look at ...

A high throughput screen of >30,000 diverse repressor domains from across the tree of life identifies repressor domains with unique structures that underpin enhanced epigenetic effector domain ...

Axsome Therapeutics has entered into a settlement agreement with Hikma resolving patent litigation related to Axsome’s product Sunosi (solriamfetol). The litigation, which is pending in the ...

Axsome Therapeutics AXSM announced that it has entered into a settlement agreement with Hikma Pharmaceuticals related to patents for its narcolepsy drug, Sunosi (solriamfetol). The settlement ...